眼眶淋巴瘤的单克隆抗体治疗。
Monoclonal antibody treatment of orbital lymphoma.
作者信息
Sullivan Timothy J, Grimes David, Bunce Ian
机构信息
Department of Ophthalmology, University of Queensland, Royal Brisbane Hospital, Herston, Queensland, Australia.
出版信息
Ophthalmic Plast Reconstr Surg. 2004 Mar;20(2):103-6. doi: 10.1097/01.iop.0000115594.98470.ac.
PURPOSE
To describe the use of an anti-CD20 monoclonal antibody, Rituximab, in the treatment of orbital lymphoma.
METHODS
Prospective, noncomparative, interventional case series of 8 patients treated with rituximab. Management, side effects, and outcome were recorded.
RESULTS
Five patients had initial complete response, 2 had partial response, and 1 had no response to this treatment. One patient had breathlessness, bronchospasm, and hypotension but was able to complete treatment. Mean follow-up was 16.5 months (range, 6 to 32 months).
CONCLUSIONS
Rituximab is a safe and effective treatment in some cases of orbital lymphoma and may be used as an alternative to, or in conjunction with, other therapeutic modalities.
目的
描述抗CD20单克隆抗体利妥昔单抗在眼眶淋巴瘤治疗中的应用。
方法
对8例接受利妥昔单抗治疗的患者进行前瞻性、非对照性、干预性病例系列研究。记录治疗管理、副作用及结果。
结果
5例患者初始完全缓解，2例部分缓解，1例对此治疗无反应。1例患者出现呼吸急促、支气管痉挛和低血压，但能够完成治疗。平均随访16.5个月（范围6至32个月）。
结论
利妥昔单抗在某些眼眶淋巴瘤病例中是一种安全有效的治疗方法，可作为其他治疗方式的替代方法或与之联合使用。
Zotero 插件